We have recently illustrated that nebivolol can inhibit angiotensin II (Ang II)-mediated
signaling in cardiomyoblasts; however, to date, the detailed mechanism for the beneficial …

Objectives Considering the complementary nature of signalling mechanisms and the
therapeutic effects of nebivolol, a β1-adrenoreceptor antagonist, and valsartan, an …

Nebivolol is a β1-adrenergic receptor antagonist that also reduces blood pressure by
evoking endothelial NO production and vasodilation. We aimed at assessing whether …

Here, we, for the first time, compared the cardioprotective effects of third-generation
vasodilating beta-blocker nebivolol (Neb) and conventional beta-blocker metoprolol (Met) …

Nebivolol, third-generation β-blocker, may activate β3-adrenergic receptor (AR), which has
been emerged as a novel and potential therapeutic targets for cardiovascular diseases …

The antihypertrophic effect of nebivolol over cardioselective beta-blockers (β-blockers) is
attributed to the activation of cardiac nitric oxide signaling. However, the precise role of …

Nebivolol is a highly selective β1-adrenoceptor blocker with additional vasodilatory
properties, which may be due to an endothelial-dependent β3-adrenergic activation of the …

Background Hypertension is the the primary cause of diastolic heart failure. Oxidative stress
plays an important role in cardiac diastolic dysfunction caused by hypertension. The …

Angiotensin II (ANG II) has profound effects on the development and progression of
pathological cardiac hypertrophy; however, the intracellular signaling mechanisms are not …

Background Cardiac hypertrophy is an adaptive process of the heart in response to various
stimuli, but sustained cardiac hypertrophy will finally lead to heart failure. Sulforaphane …